Revolutionizing Crohn’s Disease Treatment: TRX103 Gains FDA Clearance
Tr1X, a trailblazing biopharmaceutical company, has announced a significant milestone in the fight against treatment-refractory Crohn’s Disease. The FDA has granted clearance for the Investigational New Drug (IND) application of their innovative therapy, TRX103, an allogeneic engineered Tr1 Treg cell therapy. This breakthrough offers new hope for patients who have not responded to conventional treatments. […]